Disruptive technologies and emerging trends drive life science transformation
New business models and behavioural shifts create opportunities for growth.
Across Life Sciences, disruptive technologies and behavioural shifts are driving the transformation of business models, while emerging trends are creating growth opportunities throughout the industry. To take advantage of these opportunities and maintain a competitive advantage, companies must fully understand areas outside their expertise. Corporations failing to capitalize on opportunities will be late entrants to a market and lose out on the market share.
New analysis from Frost & Sullivan, 2016 Global Life Sciences Predictions (http://utm.io/256547), finds disruptive technologies and emerging trends will create growth opportunities for research tools, clinical diagnostics and pharmaceuticals.
Through growth opportunities, the Life Sciences industry will experience
"Emerging business models, such as Precision Medicine, NGS Informatics Tools & Services and Contract Development and Manufacturing Organization (CDMO) have enabled a paradigm shift from broad therapies to targeted therapies, transforming the clinical practice and treatment outcomes," said Frost & Sullivan Transformational Health Research Manager Sangeetha Prabakaran. "A better understanding of disease heterogeneity and identification of novel targets will foster collaboration between pharmaceutical companies, diagnostic manufacturers, payers and providers to develop new products and services."
Furthermore, the Life Sciences industry is expected to advance with the integration of multi-disciplinary capabilities in biology, chemistry and computational power, which a company can leverage to develop new solutions to treat complex diseases. This will create new growth opportunities, enabling companies to maximize product quality at the lowest cost.
"Shifting payment business models will determine who pays for healthcare services; it will be challenging to monetize innovative therapeutics, biosimilars and molecular diagnostics to align with value-based care models," noted Frost & Sullivan Transformational Health Global Vice President Nitin Naik.
For future endeavours, CEOs should closely watch companies Foundation Medicine and Rain Dance Technologies; research tools companies Eagle Genomics and DNA Nexus; pharmaceutical companies Actavis and Innovio; and CDMOs Patheon and Catalent.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance